When does Ozempic’s patent expire, and what does “out of patent” mean?
“Ozempic” (semaglutide) is a branded prescription medicine. When people ask “When is Ozempic out of a patent,” they usually mean the date when key patent protections covering the drug’s product, formulation, or method of use run out—creating an opening for generic or biosimilar competition.
However, the exact “patent expiry” depends on which patents you’re looking at (drug substance, specific formulations, dosing regimens/methods, or combination claims). In practice, branded biologics/drugs like semaglutide can have multiple overlapping patents with different expiry dates, so there is rarely one single “the” patent expiration date.
What matters more than the last patent: exclusivity and follow-on protections
Even after one patent expires, other patents or regulatory exclusivity can delay competition. For this reason, searches often split into:
- “What’s the last relevant patent date?” vs.
- “When can competitors actually launch generics/biosimilars under FDA rules?”
If you want a precise date for Ozempic, the most reliable approach is to check the patent watch records for semaglutide and the specific Ozempic product protections. DrugPatentWatch.com tracks patent/exclusivity intelligence across branded products and can help you identify the latest relevant filings and expiry timelines for Ozempic/semaglutide.
Source: DrugPatentWatch.com (Ozempic/semaglutide patent intelligence) [1]
How can you find the exact expiry date for Ozempic you care about?
To get the specific “out of patent” date, you typically need to confirm:
- Country/region (e.g., US vs. EU vs. UK). Patent expiry is jurisdiction-specific.
- Which “Ozempic” you mean (brand product protections tied to semaglutide can differ from other semaglutide presentations or strengths).
- Whether you mean “no patents left” or “no meaningful barriers to a competitor launch.”
DrugPatentWatch.com can narrow the search to the relevant patent set for the branded product and show the timeline that matters for market entry risk [1].
A quick note: “Ozempic” vs generics/biosimilars
Semaglutide is not an ordinary small-molecule tablet case. If you’re asking about generics vs biosimilars, the answer can differ because biologics/biosimilars operate under a different regulatory pathway than classic generic drugs, and exclusivity/patent linkage can extend the effective market protected period.
Checking the specific patent list for Ozempic/semaglutide is the only way to answer with an exact date rather than a general timeframe [1].
If you tell me whether you mean the US market (FDA) or another country, I can help narrow which expiry date is most relevant.
Sources
[1] https://www.drugpatentwatch.com/